“manocept, a derivative of fda-approved 99mtc-tilmanocept, exhibits diagnostic potential by...

23
FDA-approved 99mTc- Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug Nicholas Young 1 , Thomas J. Rosol 1 , Larry S. Schlesinger 1 , Frederick O. Cope 2 , Ramiro E. Toribio 1 , Wael Jarjour 1 1 The Ohio State University Wexner Medical Center, Columbus, Ohio, USA 2 Navidea Biopharmaceuticals, Inc., Dublin, Ohio, USA June 11 th EULAR 2015

Upload: nicholas-young

Post on 15-Apr-2017

448 views

Category:

Science


0 download

TRANSCRIPT

Page 1: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug

Nicholas Young1, Thomas J. Rosol1, Larry S. Schlesinger1, Frederick O. Cope2, Ramiro E. Toribio1, Wael Jarjour1

 1The Ohio State University Wexner Medical Center, Columbus, Ohio, USA2Navidea Biopharmaceuticals, Inc., Dublin, Ohio, USA

June 11th

EULAR 2015

Page 2: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Financial Interests Disclosure: I have no financial interests relative to this project to declare

Competing Interests Disclosure:Dr. Wael Jarjour- scientific advisory board member for

Macrophage Therapeutics (a division of Navidea Biopharmaceuticals, Inc.)

2

Page 3: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Manocept Platform

3

Glucose Backbone

Mannose

Therapeutics -Cytotoxins -Antagonist -Agonist

CD206Macrophage receptor

Page 4: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Lymphoseek

99mTc-Tilmanocept (Lymphoseek) gamma emitting metastable isotope

half-life of 6.02 hours binds with high affinity and specificity to macrophage mannose receptor (MR, CD206)

Currently to facilitate preoperative and intraoperative lymphatic mapping identification of sentinel lymph nodes

4

Wallace, A.M., et. al. Ann surg oncol 20:2590-2599, 2013.

Agrawal A., et. al. Ann surg oncol Online First- Feb, 2015.

Cope F, et al.. Nature; Supplement: Medical Imaging, 502(7473), 2013.Azad AK, et al. Journal of Cytology and Molecular Biology. 1:1, 2014.Azad AK, et al. J. Immunol. In revision.

Page 5: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Hypothesis

CD206 is a suitable biomarker to target in rheumatoid arthritis for diagnostic and therapeutic development using Manocept

5

Page 6: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) is a chronic,

systemic disease causing autoimmune

inflammation and pathology throughout the body most noticeably in the joints

In the affected joints, RA is characterized by

macrophage infiltration and joint destruction. macrophages are key players in RA and are present in the synovium of a joint

affected by RA joint inflammation in RA patients can lead to crippling loss of function and severe

chronic pain

6

https://www.rheumatology.org/Practice/Clinical/Patients

Page 7: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

RA - diagnosis

The most common tests for RA are negative 20% of the time with presentation of clinical symptoms

There are currently a few tools that are available to assess RA disease activity.

There is a clear need to develop agents for imaging RA

7

http://www.uofmhealth.org/health-library/zm6061

Page 8: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Objective

Determine if Manocept can be used as imaging agent in rheumatoid arthritis to provide

an effective diagnostic tool for prodromal RA to use as a monitor of disease activity or to

measure therapeutic responses

8

Page 9: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Macrophages Lymphocytes

CD206

MDM—CD206 detection and specificity

9

Page 10: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

MDM--Manocept

CD

14

Macrophages

Lymphocytes

Manocept

1 ml Manocept 10 ml Manocept

10

Page 11: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

11

Flow Cytometry of RA Synovial FluidManocept+

46.9 CD206+45.5

CD68+45.8

Manocept

Page 12: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Manocept detection is specific to RA (flow cytometry)

12

Manocept

Manocept+ / CD16+ Manocept+ / CD16+

OA RA

Page 13: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Image Key: Red, Manocept-Cy3; blue (DAPI).

Manocept detection in synovial tissue from a RA patient with binding specificity

DAPI

Manocept 10x “cold” pre-incubation Merge

Page 14: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

14

Manocept-Cy3 co-localization with CD206 in RADAPI CD206 Manocept-cy3 Merge

RA

OA

Healthy

Page 15: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

15

Manocept detection is specific to RA (histology)

Page 16: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Manocept-Cy3 in an in vivo model of RA Induction of RA in mice

Dba1 mice injected IP with Ab cocktail of 5 anti-cartilage antibodies

IP of E. coli LPS 3 days later Joints become swollen and have restricted motion by

day 6 Epifluorescent Imaging: ex vivo by IVIS performed

on days 7 and 9 2 hours after Manocept IV injection

Histology: Knee histopathology scored, H&E, F 4/80 16

Page 17: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

in vivo model of RA---H&E

Control mouse

RA mouse

Control mouse RA mouse

17

Page 18: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

in vivo model of RA---F 4/80

18

Control mouse RA mouse

Page 19: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

19

Manocept-cy3 co-localization with CD206 in RA animal model

Control mouse

RA mouse

Control mouse

RA mouse

Control mouse

RA mouse

Elbow

Knee

Spleen

Page 20: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Control mouse

20

Manocept-Cy3 can image inflamed joints

RA mouse

Elbow Knee

Control mouse

RA mouse

Page 21: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Results Manocept can be used to identify mannose receptor Flow cytometry:

macrophages in RA synovial fluid Levels of CD206 and Manocept are similar Manocept is detected with macrophage markers in RA synovial fluid

• Immunofluorescent microscopy:• Manocept+ / CD206+ co-localization is observed in RA synovial tissue,

but not in OA or healthy tissue• Manocept+ labeling is significantly greater in RA compared to OA or

healthy tissue• OA signals do not differ significantly from healthy tissue

• IVIS:• Manocept can be detected in inflamed joints in an

in vivo animal model of RA21

Page 22: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Conclusion

Manocept-targeting of macrophages has the potential to detect immune-mediated inflammation in RA and could be used diagnostically or to monitor therapeutic efficacy

Future work: Build human cohort of prodromal and established

patients to test Lymphoseek Explore and further develop the cytotoxic, antagonistic,

and agonistic linkers to the Manocept platform

22

Page 23: “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an

Acknowledgements

Wael Jarjour, MDLai-Chu Wu, PhDHareth Madhoun, DOJeffrey HamptonMichael BrussAmanda KiblerHolly Steigelman

The Ohio State University Wexner Medical Center, Columbus, OHDepartment of Internal MedicineDivision of Rheumatology and Immunology

Department of Microbial Infection and ImmunityCenter for Microbial Interface Biology

Navidea Biopharmaceuticals, Dublin, OH

Frederick Cope, PhD MS FACN

The Ohio State University College of Veterinary Medicine

Larry S. Schlesinger, MDAbul K. Azad, PhDMurugesan V.S. Rajaram, PhD

Thomas Rosol, DVM, PhDRamiro E. Toribio, DVM, MS, PhDBrad Bolon, DVM, MS, PhD

24

[email protected]